Results 201 to 210 of about 131,053 (266)

Using Multistate Models and Qualitative Interviews to Comprehensively Characterize Substance Use Disorder Care Transitions in a US Health Care System: Protocol for a Mixed-Methods Study. [PDF]

JMIR Res Protoc
Glass JE, Wong ES, Beatty TC, Bobb JF, Brown R, Fishman P, Idu A, Lin JYL, Matson TE, Palazzo L, Ramaprasan A, Zabinsky ZB, Hyun N.   +12 more
europepmc   +1 more source

Phenotypic Clues in Infantile‐Onset Parkinsonism‐Dystonia‐2: A Treatable Neurotransmitter Disorder

Movement Disorders Clinical Practice, EarlyView.
Sangeetha Yoganathan, Haya S. AlFaris, Lindsey Vogt, Michele Eid, Anika Menetrey, Sayoni Roy Chowdhury, Dawn Codeiro, Pradeep Krishnan, Liali Aljouda, Emily W.Y. Tam, Carolina Gorodetsky   +10 more
wiley   +1 more source

A farewell to professor Stefan Agewall from the ESC Working Group on Cardiovascular Pharmacotherapy. [PDF]

Eur Heart J Cardiovasc Pharmacother
Dobrev D, Kaski JC, Rocca B, Drexel H, Lewis BS, Niessner A.   +5 more
europepmc   +1 more source

Association of psychotropic medications with the use of coercive measures and recidivism during forensic psychiatric care: a Swedish nationwide register-based study. [PDF]

BMJ Ment Health
Sitter TM, Savinen S, Andiné P, Fernqvist A, Edberg H, Brikell I, D'Onofrio BM, Hirvikoski T, Kuja-Halkola R, Szwajda A, Fazel S, Nilsson T, Chang Z.   +12 more
europepmc   +1 more source

Severe Lower Limb and Abdominal Edema Associated with Subcutaneous Apomorphine Infusion

Movement Disorders Clinical Practice, EarlyView.
Guillaume Costentin, David Maltête
wiley   +1 more source

Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP‐1 Receptor Agonist

Movement Disorders Clinical Practice, EarlyView.
Hannah Kelly, Thomas Davis
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pharmacotherapy of obesity

Clinics in Dermatology, 2004
Whereas several drugs to treat most other chronic conditions have been developed over the last 30 years, progress in pharmacologic therapy for obesity has been slow. The record of drug treatment for obesity partly explains this phenomenon and is of concern. Several compounds have been withdrawn when severe side effects have been discovered. The lack of
Yvonne, Linné, Stephan, Rössner
openaire   +4 more sources

Pharmacotherapy of fibromyalgia

American Journal of Health-System Pharmacy, 2011
Published evidence on the pathophysiology, diagnosis, and treatment of fibromyalgia is reviewed, with an emphasis on recent clinical trials of various pharmacologic agents.Fibromyalgia affects an estimated 2% of the general U.S. population, and its incidence is sevenfold higher among women.
Laura M, Traynor, Christopher N, Thiessen, Andrew P, Traynor   +2 more
openaire   +4 more sources

Pharmacotherapy of Fibromyalgia

Rheumatic Disease Clinics of North America, 2009
Advances have occurred in the pharmacotherapy of fibromyalgia (FM) and the methodology of clinical trial design in FM in parallel with improved understanding of the underlying pathophysiologic mechanisms. Several medications have been approved for the management of FM based on their clinically meaningful and durable effect on pain in monotherapy trials
Philip J, Mease, Ernest H, Choy
openaire   +2 more sources